Filing Flows

Filing Flows › 8-K events › Abvc Biopharma

Abvc Biopharma: entry into a material definitive agreement

Form 8-K filed Nov 2, 2026 · items 1.01, 1.02, 2.03, 3.02, 5.07, 7.01

Share offeringsABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million

What the filing says

Private Placement of Senior Convertible Promissory Notes On October 30, 2026 (the “ Closing Date ”), ABVC BioPharma, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ SPA ”) with certain accredited investors (the “ Purchasers ”) for the sale of original issue discount senior convertible promiss

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 1.02: 0.0% next session across 2,368. Item 2.03: 0.0% next session across 13,268. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Other recent share offerings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.